Leerink Partnrs Weighs in on Editas Medicine Q1 Earnings

Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Editas Medicine in a report released on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar expects that the company will post earnings per share of ($0.46) for the quarter. The consensus estimate for Editas Medicine's current full-year earnings is ($2.71) per share. Leerink Partnrs also issued estimates for Editas Medicine's Q2 2025 earnings at ($0.33) EPS.

Editas Medicine Price Performance

Shares of NASDAQ:EDIT traded up $0.18 during midday trading on Thursday, hitting $1.51. The company had a trading volume of 1,849,832 shares, compared to its average volume of 2,576,600. Editas Medicine has a 12-month low of $0.91 and a 12-month high of $6.69. The company has a fifty day moving average of $1.47 and a two-hundred day moving average of $1.87. The company has a market cap of $125.98 million, a price-to-earnings ratio of -0.59 and a beta of 2.16.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.16). Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%. The business had revenue of $30.60 million during the quarter, compared to analysts' expectations of $37.17 million. During the same period in the previous year, the business posted ($0.23) EPS.

Institutional Investors Weigh In On Editas Medicine

Institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC bought a new position in shares of Editas Medicine during the fourth quarter worth $1,843,000. Balyasny Asset Management L.P. increased its stake in shares of Editas Medicine by 647.3% during the fourth quarter. Balyasny Asset Management L.P. now owns 1,300,604 shares of the company's stock valued at $1,652,000 after buying an additional 1,126,569 shares during the period. Monaco Asset Management SAM bought a new stake in shares of Editas Medicine in the fourth quarter valued at about $1,359,000. Two Sigma Advisers LP grew its holdings in Editas Medicine by 46.8% during the 4th quarter. Two Sigma Advisers LP now owns 1,657,000 shares of the company's stock worth $2,104,000 after acquiring an additional 528,000 shares in the last quarter. Finally, Tang Capital Management LLC purchased a new position in Editas Medicine during the 4th quarter valued at about $508,000. 71.90% of the stock is owned by institutional investors.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.